Low-dose esketamine for the prevention of emergency agitation in children after tonsillectomy: A randomized

Qi Li1, Jiaming Fan2, Wangping Zhang2

  • 1Department of Anesthesiology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.

Insights

Low-dose esketamine significantly reduced emergency agitation in children after tonsillectomy. This intervention did not prolong extubation or increase side effects, offering a safe option for pediatric anesthesia.

Area of Science:

  • Anesthesiology
  • Pediatric Surgery
  • Pharmacology

Background:

  • Emergency agitation is a frequent postoperative complication in children undergoing general anesthesia.
  • Tonsillectomy is a common pediatric surgical procedure where this complication is observed.

Purpose of the Study:

  • To investigate the efficacy of a low dose of esketamine in mitigating emergency agitation in pediatric patients post-tonsillectomy.
  • To evaluate the safety profile of low-dose esketamine in this patient population.

Main Methods:

  • A prospective study involving 80 children undergoing tonsillectomy, randomized into esketamine and control groups.
  • Standardized anesthesia protocols were used; the esketamine group received 0.25 μg/kg esketamine post-surgery.
  • Key metrics included extubation time, eye-opening time, Ramsay sedation scale, PACU discharge time, and postoperative complications.

Main Results:

  • The incidence of emergency agitation was significantly lower in the esketamine group (5%) compared to the control group (27.5%).
  • Eye-opening time was slightly prolonged in the esketamine group (17.2 min vs. 15.5 min).
  • Extubation time and PACU discharge time remained comparable between groups, with no increase in other adverse events.

Conclusions:

  • Low-dose esketamine effectively reduces emergency agitation in children after tonsillectomy.
  • This intervention is safe and does not negatively impact recovery times or increase other postoperative complications.

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
112
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
181
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
242